Evidence & regulatory context
- Mechanism
- No confident ChEMBL drug/compound match by name (haematopoietic prostaglandin D synthase inhibitor tool compound).
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryContusionHPGDS knockout and wild-typeFemaleSystemic
Model: Spinal cord contusion injury
HPGDS deficiency or the inhibitor HQL-79 reduced secondary tissue damage and improved locomotor recovery after spinal cord contusion, indicating a detrimental role of PGD2.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
